Is Norditropin Approved for Adult Growth Hormone Deficiency?
Yes, Norditropin (somatropin) is FDA-approved for replacement therapy in adults with growth hormone deficiency (GHD). The approval covers adults who have confirmed GHD, either alone or with multiple hormone deficiencies from pituitary or hypothalamic disease, surgery, radiation, or trauma. Diagnosis requires documented GHD in childhood or adulthood, often via insulin tolerance testing or other stimulation tests.[1][2]
How Is It Used in Adults?
Adults start at 0.1-0.2 mg/day (about 0.2-0.4 mg/kg/week), titrated up based on IGF-1 levels, body composition, and side effects. It's given daily via subcutaneous injection using Norditropin's FlexPro pen. Therapy aims to normalize IGF-1 without exceeding normal ranges, with monitoring every 1-2 months initially.[1][3]
What Do Clinical Trials Show for Adults?
Pivotal trials demonstrated Norditropin increases lean body mass, reduces fat mass, improves lipid profiles, and boosts bone mineral density over 1-2 years. A 12-month study in 369 adults showed 2.3 kg lean mass gain and 2.1 kg fat loss versus placebo. Long-term data (up to 8 years) confirm sustained benefits but note risks like fluid retention.[2][4]
Common Side Effects in Adult Patients
Most issues are mild: injection-site reactions (up to 40%), arthralgias (30%), edema (25%), and muscle pain (20%). Rare serious risks include glucose intolerance, intracranial hypertension, or malignancy progression. Adults over 60 or with diabetes need closer monitoring. Discontinue if active malignancy develops.[1][3]
Who Should Avoid Norditropin?
Contraindicated in acute critical illness, active malignancy, or hypersensitivity. Use caution in diabetes, hypothyroidism, or obesity, as these affect dosing. Not for idiopathic short stature in adults or athletic enhancement—off-label use is illegal and risky.[1][2]
Cost and Access for Adults
A month's supply (e.g., 15 mg FlexPro pen) costs $1,000-$2,000 without insurance. Patient assistance programs like Novo Nordisk's cover eligible uninsured or underinsured adults. Prior authorization requires GHD diagnosis and IGF-1 documentation.[5]
How Does It Compare to Other GH Therapies?
Similar to Genotropin, Humatrope, or Omnitrope—all recombinant human GH with comparable efficacy in adult GHD. Norditropin's pen is user-friendly for daily dosing, but all carry black-box warnings for increased mortality in critically ill patients.[1][6]
Sources
[1]: Norditropin Prescribing Information (FDA)
[2]: Novo Nordisk Norditropin HCP Site
[3]: Endocrine Society GHD Guidelines
[4]: PubMed: Long-term Norditropin in Adult GHD
[5]: Drugs.com Norditropin Pricing
[6]: FDA GH Product Approvals